A Chikungunya virus vaccine candidate that primes immune cells called CD8 T-cells is moving toward a first-in-human trial in the UK within three to six months of project completion. Chikungunya virus, spread by mosquitoes, causes debilitating joint pain that can last months or years. No licensed vaccine exists, and the virus has spread into Europe, Asia, and the Americas, causing severe economic disruption during epidemics. The vaccine, called PepGNP-ChikV, uses gold nanoparticles carrying viral peptide fragments to stimulate T-cells. Unlike traditional antibody-based vaccines, this approach aims to clear infected cells before the virus can replicate—a process called abortive infection—potentially preventing both disease and onward transmission. If successful, this vaccine could provide long-term protection—over 20 years—against a re-emerging pathogen with no current medical countermeasure. The same platform has already shown safety and T-cell responses in Phase-1 trials for dengue and betacoronavirus vaccines in Switzerland. A universal influenza vaccine using the technology is due to enter a US Phase-1 trial later this year. The project covers preclinical development, cGMP manufacturing, and regulatory submission to the MHRA.
View original technical description
The project proposes to advance a CD8 T-cell priming Chikungunya virus (CHIKV) vaccine candidate (PepGNP-ChikV) through preclinical development, cGMP manufacture and and MHRA regulatory submission for a Phase-1 clinical trial in the UK. The overall aim of this project is be ready to move into a Phase-1 clinical trial within 3 to 6 months of completion of this project. CHIKV is a mosquito-transmitted alphavirus that causes epidemics of illness characterized by debilitating arthralgia and arthritis that can endure for months to years following infection. In the last decade, CHIKV has become a reemerging mosquito-transmitted virus that has spread into Europe, Asia, the Pacific Region, and the Americas, with epidemics causing severe economic impact. No licensed vaccine exists. Emergex has developed a unique T-cell priming vaccine platform comprised of two technologies: a library of expressed major histocompatibility complex (MHC) Class 1-restricted viral specific peptides, and a self-adjuvating gold nanoparticle (GNP) carrier system. Emergex believes that T-cell priming vaccines offer an effective means to prevent disease and transmission for a range of pathogens including Chikungunya. T-cell priming vaccines have the advantage that since they target human cells at the stage of initial viral infection, they can clear the viral pathogen before it has the opportunity to replicate (Termed "abortive infection"). This would prevent both clinical disease and transmission. The T-cell prime system also has the capacity for long term protection (\>20 years). Using the Emergex platform, two products (A Dengue vaccine and a Betacoronavirus vaccine) have completed Phase-1 trials in Switzerland (NCT04935801 and NCT04935801). The vaccines were shown to be safe and capable of inducing significant vaccine specific T-cell effector and memory responses. Regulatory approval has been given for a phase 1b trial for the betacoranavirus vaccine due to begin imminently. These vaccines will be advanced in Phase-2 trials. A universal influenza vaccine is due to enter a Phase-1 trial in the USA in Q4 this year. This project will advance upon outputs from the previous competition "SBRI - Vaccines for epidemic diseases: Readiness for clinical development and regulatory submission". In this competition Emergex met all milestones and 1) identified the Chikungunya peptide epitope library using immunoproteomics 2) synthesized an experimental vaccine candidate using those epitope sequences 3) Showed in vitro efficacy of the candidate. Based on these outputs, Emergex believe the candidate is now in a state of readiness to enter formal preclinical development and cGMP manufacture.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know